Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Sutro Biopharma, Inc.NASDAQ: STRO

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -$8.89M, compared with -$7.45M a year earlier. Trailing-twelve-month other income / expenses was -$38.64M.

Context

  • Other income / expenses amounted to 84.1% of revenue in FY2025, up 62.6 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$8.89M or moves back toward the trailing-twelve-month quarterly average of -$9.66M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.89M+32.6% QoQ
Last fiscal yearDec 2025
-$86.23M-745.7% YoY
LTMMar 2026
-$38.64M-613.7% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.2%——
1 year-745.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(86.23M) USD
Year-over-year change
-745.7%

Other Income / Expenses vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -613.7% is the lowest of 9, against a peer median of -60.7%.
  • Other income / expenses amounts to 38.8% of revenue for STRO, versus a peer median of 889.8%.
STRO Competitors
Other Income / Expenses for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$5.99M USD-61.1%-42.7%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5M USD-50.6%+65.3%—
KLRSKalaris Therapeutics IncLTM Mar 2026$3.53M USD+1344.0%——
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$5.37M USD-124.3%—11.9%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$15.12M USD-297.9%——
STROSutro Biopharma, Inc.LTM Mar 2026-$38.64M USD-613.7%—38.8%
Peer median (excluding STRO) —-60.7%+22.4%889.8%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.